Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE Epidermal growth factor receptor tyrosine kinase inhibitors therapy, such as gefitinib, have proven to be effective for lung adenocarcinoma with epidermal growth factor receptor-sensitive mutations. 31503013 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 Biomarker disease BEFREE Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma. 31671073 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. 31760310 2020
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.700 Biomarker disease BEFREE In this study, we aim to validate diagnostic performance of multiplex ALK/ROS1 fluorescence in situ hybridisation (FISH) approach in lung adenocarcinoma cytological series compared with classic single break apart probes. 31562206 2020
Entrez Id: 238
Gene Symbol: ALK
ALK
0.700 Biomarker disease BEFREE A 47-year-old female with ALK-rearranged lung adenocarcinoma developed leptomeningeal metastasis (LM) after progression on first-line crizotinib. 31766077 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE The mutational landscape in lung adenocarcinoma (LADC) is broadly recognized, particularly regarding the presence of the epidermal growth factor receptor (EGFR) mutation in non-smokers. 31599770 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE EGFR mutations were found more frequently in females (63.11%), never-smokers (59.69%), and those with lung adenocarcinoma (ADC) (53.87%). 31707279 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Our study revealed that concurrent genomic alterations can further stratify KRAS-mutant lung adenocarcinoma patients into various subgroups with distinctive therapeutic responses and differential survival outcomes. 31709742 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 GeneticVariation disease BEFREE Despite substantial progress in lung cancer immunotherapy, the overall response rate in KRAS-mutant lung adenocarcinoma (ADC) patients remains low. 31744829 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE We present a case of a 78-year-old man who was diagnosed with stage IV non-small cell lung adenocarcinoma with an EGFR exon 20 mutations treated with pemetrexed, nivolumab, and then docetaxel. 30760168 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE For patients with EGFR-mutation-positive lung adenocarcinoma associated with paraneoplastic membranous nephropathy, erlotinib might serve as a treatment option for both the tumour and the membranous nephropathy. 31730733 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE Prognostic factors of EGFR-mutated metastatic adenocarcinoma of lung. 31846863 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE The model was prognostically significant in stratified cohorts, including stage I-II, stage III-IV and epidermal growth factor receptor (EGFR) mutant subsets, and was considered to be an independent prognostic factor for LUAD. 31779055 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 Biomarker disease BEFREE However, epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitor (TKI) resistance is a major challenge in the treatment of advanced and recurrent EGFR‑mutant lung adenocarcinoma. 31789388 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 Biomarker disease BEFREE In conclusion, our data describe an essential role for mPRα in improving sensitivity to EGFR-TKIs, thus rationalizing its potential as a therapeutic target for lung adenocarcinomas. 31777985 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE Intense Expression of EGFR L858R Characterizes the Micropapillary Component and L858R Is Associated with the Risk of Recurrence in pN0M0 Lung Adenocarcinoma with the Micropapillary Component. 31732945 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE The introduction of liquid biopsy using PCR-based assays into routine practice has had a strong impact on the treatment of EGFR-mutated lung adenocarcinoma and is now commonly used for routine testing of EGFR mutations in certain clinical settings. 31519454 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.700 Biomarker disease BEFREE The KRAS gene is the second most frequently mutated gene in LUAC and the majority of KRAS mutations are one of three classical activating mutations (G12, G13, and Q61). 31787238 2020
Entrez Id: 238
Gene Symbol: ALK
ALK
0.700 GeneticVariation disease BEFREE Moreover, the concordance of ALK status was observed in these pairs.<b>Conclusions</b>: Our data suggested that hotspot mutations and ALK status in the primary-metastasis pairs had a high concordance in lung adenocarcinoma. 31651223 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE The concordance rate demonstrated the feasibility of EGFR mutations in corresponding metastases using Amplification Refractory Mutation System when the primary tumor tissue is unavailable in the lung adenocarcinoma patients, and the inconsistency indicates that corresponding metastasis being screened simultaneously with the primary tumor samples may present some supplementary information for the patients. 30601156 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE The patient was diagnosed with lung adenocarcinoma with an EGFR L861Q mutation based on cytological findings. 31779047 2020
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 Biomarker disease BEFREE Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization. 31668800 2020
Entrez Id: 238
Gene Symbol: ALK
ALK
0.700 Biomarker disease BEFREE In this study, we aim to validate diagnostic performance of multiplex ALK/ROS1 fluorescence in situ hybridisation (FISH) approach in lung adenocarcinoma cytological series compared with classic single break apart probes. 31562206 2020
Entrez Id: 238
Gene Symbol: ALK
ALK
0.700 GeneticVariation disease BEFREE The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas. 31215177 2019
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.700 GeneticVariation disease BEFREE Compared with chemotherapy, use of the 1st generation of EGFR-TKIs as first-line therapy can improve the short-term efficacy of patients with EGFR uncommon mutations advanced lung adenocarcinoma, but platinum-based chemotherapy showed a longer overall survival. 30885350 2019